Meeting Banner
Abstract #1722

Imaging the Timing of Cytotoxic and Anti-Angiogenic Therapy

Gregory L. Pishko1, Morad Nasseri1, Seymur Gahramanov1, Leslie L. Muldoon1, Edward A. Neuwelt1, 2

1Oregon Health & Science University, Portland, OR, United States; 2Veterans Affairs Medical Center , Portland, OR, United States

Timing and sequencing of chemotherapy and anti-angiogenic therapy may play an important role in anti-brain tumor efficacy. A pilot study was conducted to use MRI to elucidate vascular and interstitial fluid differences that correspond with the timing of temozolomide (chemotherapy) and bevacizumab (anti-angiogenic) delivery. Rats with intracerebrally implanted human gliomas were randomized to three treatment groups: control, bevacizumab followed by temozolomide 4 days later, and temozolomide followed by bevacizumab 4 days later. Permeability measurements and T2W imaging demonstrated that it may be more effective to deliver chemotherapy before anti-angiogenic therapy and warrants further study.

Keywords

accomplished affairs agents aimed animal animals anti apparent appears arterial audience background barrier better blood brain cancer cells chemotherapy clinical compartment compromised consequences control correspond course cytotoxic days decrease decreased deliver delivered delivering delivery density detection drug drugs edema effective efficacy elucidate environment fast fitting fluid foreground functions goal gradient health heterogeneity histology human impact implemented important indicate inoculated input interstitial limiting magnet maps medical model necrosis neurology nonlinear normalization normalize nucleus often oral overall path permeability pilot post previous prior promise proton quantification quantify raises randomized rats reached reduced regimen remains represent researchers reversal science sequencing spatial squared subsequent system systemically target therapies therapy timing trans treated treatment tumor tumors unclear understand vascular veterans volumes walker warrants